Division of Biostatistics, IHE
Medical College of Wisconsin presents

Design and Analysis Considerations for an Umbrella Trial for Acute Myeloid Leukemia

By: Megan Othus, PhD

JOIN US!

Tuesday, March 8th | 3:30PM - 4:30PM

Acute myeloid leukemia (AML) is a rare cancer of the bone marrow with very poor outcomes for many patients. Mutations that drive the biology and prognosis of AML are well characterized and therapies targeting these mutations are being rapidly developed. Measurable residual disease (MRD) is the strongest prognostic factor for AML patients and clinicians want to be able to use it to make treatment decisions, but there is not consensus on how to define MRD and how and when to use MRD to guide treatment decisions. myeloMATCH is an NCI-funded umbrella trial being developed for patients with AML with the goals to (1) evaluate both targeted and non-targeted agents in the treatment of AML and (2) to evaluate the role of MRD in AML. This talk with discuss the structure and design considerations for the screening portion of the myeloMATCH trial and also discuss some of the challenges with evaluating MRD within and across clinical trials part of myeloMATCH.

Megan Othus, PhD

Biography: Dr. Megan Othus is a Professor in the Biostatistics program at the Fred Hutchinson Cancer Research Center. Dr. Othus is the faculty statistician for the SWOG Cancer Research Network Leukemia and Rare Cancer Committees. In that role, she leads the design and analysis of the trials through the committees and the translational medicine projects associated with the trials. Her research focuses on clinical trial design and statistical analysis techniques for clinical trial data. In addition, she is interested in research questions that use SWOG historical data to inform clinical practice and trial design.

Location: WebEx | https://mcw.webex.com/mcw/j.php?MTID=m98d67ccd5c204a6bf8fe27d62bacf59d

knowledge changing life

Please contact Chelsea Rowley for additional event information at Crowley@mcw.edu.